Last reviewed · How we verify
Enalapril maleate and folic acid tablets
Enalapril maleate and folic acid tablets is a ACE inhibitor (combination with vitamin supplement) Small molecule drug developed by Shenzhen Ausa Pharmed Co.,Ltd. It is currently FDA-approved for Hypertension, Heart failure, Post-myocardial infarction cardioprotection.
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cellular methylation and DNA synthesis.
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cellular methylation and DNA synthesis. Used for Hypertension, Heart failure, Post-myocardial infarction cardioprotection.
At a glance
| Generic name | Enalapril maleate and folic acid tablets |
|---|---|
| Sponsor | Shenzhen Ausa Pharmed Co.,Ltd |
| Drug class | ACE inhibitor (combination with vitamin supplement) |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enalapril maleate is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, thereby lowering blood pressure and reducing cardiac workload. Folic acid (vitamin B9) is included as a supplementary component to support methylation reactions and reduce homocysteine levels, which may provide additional cardiovascular benefit in hypertensive patients.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction cardioprotection
Common side effects
- Dry cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
- Headache
Key clinical trials
- The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment (PHASE2, PHASE3)
- H-Type Hypertension Precision Medicine Trial (PHASE4)
- CSPPT- Chronic Kidney Diseases Study (PHASE4)
- China Stroke Primary Prevention Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril maleate and folic acid tablets CI brief — competitive landscape report
- Enalapril maleate and folic acid tablets updates RSS · CI watch RSS
- Shenzhen Ausa Pharmed Co.,Ltd portfolio CI
Frequently asked questions about Enalapril maleate and folic acid tablets
What is Enalapril maleate and folic acid tablets?
How does Enalapril maleate and folic acid tablets work?
What is Enalapril maleate and folic acid tablets used for?
Who makes Enalapril maleate and folic acid tablets?
What drug class is Enalapril maleate and folic acid tablets in?
What development phase is Enalapril maleate and folic acid tablets in?
What are the side effects of Enalapril maleate and folic acid tablets?
What does Enalapril maleate and folic acid tablets target?
Related
- Drug class: All ACE inhibitor (combination with vitamin supplement) drugs
- Target: All drugs targeting Angiotensin-converting enzyme (ACE)
- Manufacturer: Shenzhen Ausa Pharmed Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
- Indication: Drugs for Post-myocardial infarction cardioprotection
- Compare: Enalapril maleate and folic acid tablets vs similar drugs
- Pricing: Enalapril maleate and folic acid tablets cost, discount & access